RxDoctor Payments Data

Ted Gutowski, MD

Cardiovascular Disease · Freehold, NJNPI 1669476073

Payments from drug & device makers

$3,801in general payments, 2019–2025

Across 195 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Novartis$877
  • Irhythm Technologies, Inc.$271
  • Pfizer$198
  • Johnson & Johnson$157
  • Abiomed$143
  • plus $648 from 16 others

What the payments were for

  • Travel & lodging$1,03927%
  • Food & beverage$2,76273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,801 in reported general payments places this provider in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$438,869
Medicare patients
1,609
Services billed
4,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban517$704,146
XareltoRivaroxaban143$165,604
EntrestoSacubitril/Valsartan79$123,617
MultaqDronedarone Hcl56$87,335
Repatha SureclickEvolocumab52$56,315
JardianceEmpagliflozin49$41,844
Praluent PenAlirocumab28$30,462
BrilintaTicagrelor16$20,134
FarxigaDapagliflozin Propanediol23$16,835
Ezetimibe603$15,356
Metoprolol Succinate865$15,291
Rosuvastatin Calcium762$11,879
Icosapent Ethyl13$8,714
Atorvastatin Calcium744$8,391
Amlodipine Besylate702$5,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$198$704,146517 claims
Johnson & JohnsonXarelto$157$165,604143 claims
NovartisEntresto$877$123,61779 claims
Sanofi-aventis U.S. LLCMultaq$68$87,33556 claims
Boehringer IngelheimJardiance$54$41,84449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Freehold

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →